AIDS Community Research Initiative of America (ACRIA) - Fall 2003 / Winter 2004

Trizivir is not a single drug, but a formulation of three drugs into one tablet. All three drugs - Retrovir (AZT), Epivir (3TC), and Ziagen (abacavir) - continue to be available separately.

Background: The FDA approvals of Combivir (Retrovir and Epivir in one tablet) in 1997 and Ziagen in 1998 paved the way for Trizivir's approval in November 2000. Retrovir, Epivir, and Ziagen are all owned by GlaxoSmithKline, so it made sense from a commercial viewpoint to combine the drugs into one tablet.

Based on study results (see CNA3005 and, especially, ACTG 5095 described under Ziagen), using Trizivir - at least without a fourth drug - might not be a good idea for people who are just starting HIV therapy. This triple-nucleoside regimen doesn't lower viral load as much or for as long as a regimen that combines two nucleosides with a protease inhibitor (PI) or non-nucleoside (NNRTI); people with viral loads greater than 100,000 don't respond well to this regimen; and there's the potential for a Ziagen hypersensitivity reaction. On the positive side, Trizivir offers easy dosing, has few interactions with other drugs, saves PIs and NNRTIs for future use, and avoids some of the side effects associated with PIs and NNRTIs. So it may still be a useful option for people with HIV who face adherence difficulties. But the potential benefits may be outweighed by the potential risks.

The recently revised Department of Health and Human Services treatment guidelines list Trizivir as an alternative to a PI- or NNRTI-based regimen for people who have never taken antiretrovirals before, but caution that it should not be used by people with viral loads greater than 100,000. The July 2003 British HIV Association (BHIVA) treatment guidelines go even further, stating that Trizivir should not be considered for initial therapy and that it should only be used with an additional drug in a four-drug combination.

See the Retrovir, Epivir, and Ziagen entries for information about side effects, drug interactions, and other particulars.

Good To Know:

• Some physicians may prescribe Trizivir based on assumptions about an individual's inability to adhere to a more complex regimen even though another regimen may be more beneficial. Trizivir still requires twice-daily dosing, and almost all regimens can now be taken twice a day or once a day. Trizivir isn't necessarily any less challenging to adhere to than other, more powerful regimens.
  
  
• Because Trizivir is a fixed-dose formulation, it can't be used by people who require a different dose of any of the three drugs it contains.
  
  
• People who weigh less than 110 pounds shouldn't take Trizivir, since their dose of Epivir needs to be reduced.
  
  
• You may not be able to take Trizivir if you've had any kidney problems. The dose of Epivir sometimes needs to be lowered in people with kidney problems.
  
  
• People starting Trizivir may not be aware of the potentially life-threatening hypersensitivity reaction that occurs in about 5% of people who take Ziagen. Some may not be aware that Trizivir contains Ziagen. Educate yourself about the symptoms of a hypersensitivity reaction (see Ziagen entry). If you suspect that you're experiencing Ziagen hypersensitivity, call your doctor immediately. Some people who took Ziagen in the past may have experienced a hypersensitivity reaction without recognizing it. If they take Trizivir, they should be aware that it's the same as re-starting Ziagen.
  
  
• Epivir, one of the drugs in Trizivir, is also used as a treatment for chronic hepatitis B (HBV), although at a lower dose than that used for HIV. People co-infected with HIV and chronic HBV need to bear that in mind when considering Trizivir (see the Hepatitis B section in the discussion of Epivir).

Dose: One tablet twice a day, with or without food. Each tablet contains 300 mg of Retrovir (AZT), 150 mg of Epivir (3TC), and 300 mg of Ziagen (abacavir).

FDA Approval: 2000

Manufacturer: GlaxoSmithKline

Patient Assistance Program: 866-728-4368

20030910
CR030917

Copyright © 2003 - AIDS Community Research Initiative of America. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, ACRIA Update, 230 West 38th Street, 17th Floor, New York, NY 10018; (212) 924-3934; Fax (212) 924-3936 .

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. ÆGIS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content.